FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				0. 0	20000011	0(11) 01		· COUITION	Company A	0. 0	7-10							
1. Name and Address of Reporting Person* <u>Leonard Braden Michael</u>					2. Issuer Name and Ticker or Trading Symbol Reneo Pharmaceuticals, Inc. [RPHM]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director				
(Last)	st) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 08/13/2024									Officer (give title below)			r (specify w)	
65 E CEDAR - SUITE 2					4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Ch Line)											· ·		
(Street) ZIONSVILLE IN 46077				Form filed by One Reporting Person Form filed by More than One Reportin Person														
(City) (State) (Zip)				Ru	Rule 10b5-1(c) Transaction Indication													
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - Non-Deriva	tive	Secui	rities	Acqı	uired,	Disposed	of, o	r Be	eneficial	ly Own	ed				
1. Title of	Security (Ins	2. Transaction Date (Month/Day/Ye	ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Cod	nsaction le (Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Cod	le V	Amount	(A) o (D)	r _{Pi}	rice	Reported Transact (Instr. 3 a	tion(s)	Ù		,	
Common	Stock	08/13/202			P		171,339	A	\$	1.3925(2)	2,843,533		I		Holding of BML Investment Partners, L.P. ⁽¹⁾			
Common	08/14/202	4			Р		100,487	A	\$	1.4132 ⁽³⁾	2,944	4,020	I		Holding of BML Investment Partners, L.P. ⁽¹⁾			
Common Stock													1,020,769		D			
		Tal	ble II - Derivat (e.g., pu						isposed o s, conver				Owne	d				
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Executity or Exercise (Month/Day/Year) if a		3A. Deemed Execution Date, if any (Month/Day/Year)	Date, Transacti Code (Ins		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration	e Exercisable and ation Date h/Day/Year) Expiration isable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		8. Price of Derivative Security (Instr. 5) Securiti Benefici Owned Followir Reporte Transac (Instr. 4)		re (10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)	

Explanation of Responses:

- 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
- 2. Purchased in multiple transactions with a weighted average price of \$1.3925. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range
- 3. Purchased in multiple transactions with a weighted average price of \$1.4132. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.

/s/ Braden Michael Leonard 08/14/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.